Fate Therapeutics, Inc. (FATE) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	6.5M	6.6M	13.6M	63.5M	96.3M
Cost of Revenue	28.8M	12.9M	118.5M	157.2M	13.8M
Gross Profit	(22.3M)	(6.3M)	(104.9M)	(93.7M)	82.5M
Operating Expenses
R&D Expense	97.4M	107.8M	135.0M	172.6M	320.5M
SG&A Expense	39.7M	46.5M	90.6M	96.9M	84.2M
General & Admin Expense	39.7M	46.5M	74.2M	81.4M	84.2M
Selling & Marketing Expense	—	—	16.5M	15.4M	—
Other Expenses	(25.8M)	(12.9M)	(120.3M)	(172.6M)	(13.8M)
Total Operating Expenses	111.3M	141.4M	105.4M	96.9M	390.9M
Cost and Expenses	140.1M	154.3M	223.9M	254.0M	404.7M
Operating Income (EBIT)	(133.6M)	(147.7M)	(210.3M)	(190.5M)	(308.4M)
Non-Operating
Interest Income	8.2M	11.1M	17.3M	17.2M	5.8M
Interest Expense	—	—	—	—	—
Net Interest Income	8.2M	11.1M	17.3M	17.2M	5.8M
Other Non-Op Income/Expense	7.6M	11.4M	24.0M	29.6M	26.7M
Non-Operating Income (excl Interest)	(7.2M)	(11.4M)	(14.7M)	(29.6M)	(26.7M)
EBT (Pre-Tax Income)	(126.0M)	(136.3M)	(186.3M)	(160.9M)	(281.7M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(126.0M)	(136.3M)	(186.3M)	(160.9M)	(281.7M)
Earnings from Cont. Ops	(126.0M)	(136.3M)	(186.3M)	(160.9M)	(281.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(126.0M)	(136.3M)	(186.3M)	(160.9M)	(281.7M)
Per Share
Basic EPS	($1.05)	($1.15)	($1.64)	($1.64)	($2.91)
Diluted EPS	($1.05)	($1.15)	($1.64)	($1.64)	($2.91)
Revenue Per Share	$0.05	$0.06	$0.12	$0.65	$0.99
Shares
Basic Shares Outstanding	120.4M	118.8M	113.7M	98.4M	96.8M
Diluted Shares Outstanding	120.4M	118.8M	113.7M	98.4M	96.8M
Profitability Metrics
EBITDA	(117.2M)	(127.0M)	(176.6M)	(142.6M)	(268.0M)
D&A	9.2M	9.3M	19.0M	18.3M	13.8M
EBIT	(126.4M)	(136.3M)	(195.5M)	(160.9M)	(281.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026